CN1142281C - Preparation of recombined erythropoietin preparation - Google Patents
Preparation of recombined erythropoietin preparation Download PDFInfo
- Publication number
- CN1142281C CN1142281C CNB98100248XA CN98100248A CN1142281C CN 1142281 C CN1142281 C CN 1142281C CN B98100248X A CNB98100248X A CN B98100248XA CN 98100248 A CN98100248 A CN 98100248A CN 1142281 C CN1142281 C CN 1142281C
- Authority
- CN
- China
- Prior art keywords
- cell
- human erythropoietin
- erythropoietin
- substratum
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title claims description 10
- 102000003951 Erythropoietin Human genes 0.000 title claims description 7
- 108090000394 Erythropoietin Proteins 0.000 title claims description 7
- 229940105423 erythropoietin Drugs 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims abstract description 28
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims abstract description 28
- 102000044890 human EPO Human genes 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 102000004877 Insulin Human genes 0.000 claims abstract description 5
- 108090001061 Insulin Proteins 0.000 claims abstract description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 8
- 244000309466 calf Species 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- 102000002070 Transferrins Human genes 0.000 claims description 4
- 108010015865 Transferrins Proteins 0.000 claims description 4
- 150000002505 iron Chemical class 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000010412 perfusion Effects 0.000 claims description 4
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 claims description 3
- 241000699802 Cricetulus griseus Species 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 238000004007 reversed phase HPLC Methods 0.000 abstract description 6
- 239000012071 phase Substances 0.000 abstract description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 4
- 238000001042 affinity chromatography Methods 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 3
- 238000002523 gelfiltration Methods 0.000 abstract description 2
- 229940125396 insulin Drugs 0.000 abstract description 2
- 238000005342 ion exchange Methods 0.000 abstract description 2
- 239000007791 liquid phase Substances 0.000 abstract description 2
- 210000004962 mammalian cell Anatomy 0.000 abstract description 2
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 36
- 238000010828 elution Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 235000011089 carbon dioxide Nutrition 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000005374 membrane filtration Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 3
- 102100031939 Erythropoietin Human genes 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000806990 Hala Species 0.000 description 1
- 101100333654 Homo sapiens EPO gene Proteins 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 235000005311 Pandanus odoratissimus Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention discloses a method for vastly producing a human erythropoietin preparation, which comprises the steps: a nutrient culture medium added with insulin and transferrin is used for cultivating converted mammalian cells carried with human erythropoietin DNA encoding sequences under the specified culture conditions to obtain high expression of the protein product; and then the harvest liquid containing rich human erythropoietin is orderly processed by affinity chromatography, ion exchange, reversed phase high-efficiency liquid phase and gel filtration and purification by RP-HPLC and gel so as to obtain high-purity human erythropoietin having high biological activity.
Description
Technical field
The present invention relates to utilize the eukaryotic cell expression system of carrying the proteinic nucleotide sequence of coding human erythropoietin, scale operation human erythropoietin method of protein.Particularly relate to the high yield is the separation of purpose and the method for purifying height ratio living person erythropoietin.
Background technology
Human erythropoietin (hEPO) is the glycoprotein of a kind of about 36KD of molecular weight that is mainly produced by kidney.This protein can act on bone marrow stem cell effectively as a kind of normal hormone, regulates and stimulation reticulocyte and erythrocytic generation and differentiation, thereby keeps the interior normoerythrocyte quantity of peripheral circulation.Therefore can be used for treating various forms of anaemias, particularly renal anemia clinically and produce the not enough red corpuscle deficiency disease that causes because of this hormone.
U.s. patent application serial number NO.570,075 (New youk, University) and United States Patent (USP) NO.4,677,195 (Genetics Institute, Inc.) disclose respectively with the method for anti-phase immunochromatographic method from natural origin purifying human erythropoietin, the latter is 160 with the erythropoietin protein matter specific activity of anti-phase immunochromatographic method preparation, the 000IU/280nm absorbance unit.Chinese patent CN 85106191A (Corriy-Ellge Corp) discloses and has utilized eukaryotic cell and the production of procaryotic cell expression system to have the method that the natural human promoting erythrocyte generates active protein (human erythropoietin).Wherein the hEPO product activity in vivo with escherichia coli expression that obtains with reversed phase high efficiency liquid phase method has only 120-720IU/mg protein, particularly mention in the document, the contriver is respectively 2589 IU/ml and 3089 IU/ml with eukaryotic cell expression system (Chinese hamster ovary cell) acquisition EPO product is external with activity in vivo.In addition, the purity of its expression product is about 95%, and clearly lacks enough molecule homogeneity.Activity as for its prepared human erythropoietin analogue is the 1/4-1/10 of its " parental generation ".European patent application 0,232 034 public use host people cell (Hala cell) is made the method for host's fermentative production rhEPO, and wherein having mentioned its lytic activity is 490 units.PCT patent publication No. W088/00241, the method of the Apa I restriction fragment of public use COS-7 (monkey kidney) and BHK (hamster kidney) cell expression system expressing human erythropoietin gene, though should side's document do not describe the separation and the purification process of expression product, but the ratio work of the secretory product of pointing out in the embodiment 7 is 700 units/ml, estimates at the proteinic specific activity of 7800 units/ml that is equivalent to natural EPO.At last, european patent application 0,236 059 discloses to use and has had neo
xThe recombinant vectors of selectable marker gene (linear transduction vector) is expressed in mammalian cell, and with the method for affinity chromatography purifying EPO, detecting the proteinic output of proof erythropoietin through the external beam radiotherapy immunization is 100-1500 unit/10
6Cell/sky.
In sum, these current materials only with regard to the isolation and purification means of laboratory level expression product, all can not obtain gratifying effect.Particularly arrive the industrially scalable high volume production process with laboratory study, the technical difference that has essence, explore and a large amount of experiment accumulation without creativeness over a long time, although in the laboratory, successfully obtained required product, but will be with high yield, the low-cost gene engineering product that obtains high specific acitivity, as human erythropoietin, it will be impossible really realizing the commercialization of purpose product and obtain due interests.
Up to now, set up and in production practice, successfully used many from natural origin or from separating the transformant cell of DNA recombinant technology preparation and the culture thereof and the method for the purpose product that purifying is required, these methods comprise saltout, ultrafiltration, electrophoresis (as polyacrylamide gel electrophoresis, isoelectrofocusing, electrocapillary phoresis etc.), column chromatography (as ion exchange chromatography, gel chromatography, high performance liquid chromatography, affinity chromatography etc.).Because required molecular weight of product size, charging property are different with molecule electric charge number, wetting ability and iso-electric point, changing method required when separating with purified product or method combination and their order also will be complete different.Therefore finding a cover to be fit to the fermentation culture conditions that the suitability for industrialized production scale is used to recombinant bacterial strain or cell strain, to improve the product expression efficiency, and improve and separate and the purify DNA recombinant products, for example confirming the method for the recombinant human erythropoietin (rhEPO) that its effect is very clear and definite at present in clinical application, is that a this area has problem to be solved.
Summary of the invention
Eukaryotic cell (Chinese hamster ovary celI) expression system that carry coding human erythropoietin proteinic nucleotide sequence of the present invention by adopting this laboratory to make up utilizes specific substratum and culture condition and continuous chromatography method to realize.Its technical scheme main points may further comprise the steps:
Get frozen production cell strain, 39 ℃ of water-baths, centrifugal under aseptic technique.Add an amount of DMEM substratum that contains 5% foetal calf serum after abandoning supernatant, and be inoculated in the Tissue Culture Flask 37 ℃ of cultivations in the carbonic acid gas incubator.After treating the full culturing bottle wall of cell well-grown and card, continue to go down to posterity (passing the three generations) cultivates.State with microscope observing cell is fusiformis at cell, when growth conditions is good, discards old substratum,, is collected in the inoculation bottle cell dissociation with Digestive system.The cell quantity that is used to inoculate is 2.5 * 10
6Individual/ml.
The expression employing volume that contains the recombinant cell strain of human epo gene is the successive type cell reactor (hereinafter to be referred as the cell jar) of 5L, adds cellulose carrier sheet (Disc), PBS damping fluid (pH7.0), connects good pipeline, autoclaving 1.5 hours.Treat to insert main frame after the cell jar is cooled to room temperature, and connect four kinds of gases such as air, oxygen, carbonic acid gas, nitrogen.Proofreaied and correct behind the pH electrode and the DO. electrode after, discharge the PBS damping fluid in the cell jar, add the DMEM substratum that contains 5% foetal calf serum, cell inoculation liquid is slowly added in the cell jar again, regulate the stirring revolution and be lower than 50rpm/ minute, temperature is 37 ℃, feed four kinds of gases, control DO.50-80%, pH7.0 carries out adherent culture for some time.Improve revolution then by 80-100rpm/ minute, carried out the interior amplification cultivation of cell jar ten days.(but differentiation and propagation that blood serum medium effective stimulus cell is arranged).The DMEM substratum that will contain foetal calf serum is replaced by the synthetic medium of serum-free, with the cultural method of continuous perfusion substratum, uses the fermentation condition of AFS software control cell, comprises temperature, dissolved oxygen, pH value etc.The cultivation of results is based on 4-8 ℃ of low temperature storage.The expression output of hEPO can reach 10,000 IU/ml in the substratum that this working condition is gathered in the crops down.The synthetic medium of using serum-free simultaneously can reduce the content of heteroproteins in the purge process, increases the capacity of each chromatography chromatographic column, prolongs its work-ing life, effectively improves half-finished purity.The synthetic medium of used serum-free is the CHO-S-SFM-II substratum, and the amount of insulin of wherein adding is 1nM-10mM, Transferrins,iron complexes add-on 0.1nM-100nM, and the glucose add-on is the 1-10 grams per liter, the sodium bicarbonate add-on is the 2-4 grams per liter.
Get the substratum membrane filtration that obtains, with CM affinity column on certain flow velocity (in advance with the activation of NaCl-HAc-Virahol, 20mM Tris.HCl level pad balance), use level pad balance CM post more then.Adopt 0.2M NaCl-20mM Tris elutriant to carry out gradient elution, collect the activated elution peak dialysis tubing of packing into, dialyzed overnight in 10mM Tris dialyzate with certain flow rate.With the protein soln membrane filtration of the desalination of dialysing, with DEAE ion exchange column on certain flow velocity (using 10Mm Tris level pad balance in advance).Adopt the elutriant of 0.1M NaCl-Tris to carry out gradient elution, collect activated elution peak, (RP-HPLC chromatography column filler is C4 to last RP-HPLC, use acetonitrile-trifluoroacetic acid balance in advance) chromatography column, use 10% this chromatography column of acetonitrile solution balance then, the acetonitrile solution with 10-70% carries out gradient elution again.Collect activated elution peak, last gel chromatography column (using 20mM citrate buffer balance in advance) is used 20mM citrate buffer balance and wash-out again, collects activated elution peak (being hEPO).The ratio of sampling and measuring hEPO is lived, protein content, with the human serum albumin that adds 0.5% among the hEPO, makes the hEPO finished product preparation after the sterile filtration after quality inspection is qualified.Through the rh-EPO of this technology purifying, it can reach 2 * 10 than work
5IU/mg.
Embodiment
By embodiment the present invention is described for example further below, but these embodiment and not limiting the present invention in any way.
Embodiment one: the propagation of cell
Get the freeze-stored cell strain, 39 ℃ of water-baths, centrifugal under the aseptic technique (1000rpm * 5 minute).Abandon and add 5ml behind the supernatant and contain the DMEM substratum of 5% foetal calf serum (every 10L contains DMEM 135 grams, foetal calf serum 500ml, gentamicin 500,000 units, glucose 13.5 grams, sodium bicarbonate 24.5 grams) piping and druming evenly, be inoculated in the 100ml Tissue Culture Flask, add the DMEM substratum that 10ml contains 5% foetal calf serum again, in 37 ℃, the carbonic acid gas incubator (production of Forma company) of 5%CO2, cultivate.Treat that cell growth state is good, stick the culturing bottle wall after, import in four 500ml culturing bottles, and when cell is sticked bottle wall once more, import the culturing bottle of 32 bottles of 500ml into.Use the microscope observing cell growth conditions, when cell is in logarithmic phase, discard old substratum, with Digestive system (every liter contains EDTA 0.2g, glucose 1g, pancreatin 2g pH7.6) with cell dissociation, is collected in the inoculation bottle.Being used for inoculating cell quantity is 2.5 * 10
6Individual/ml, be total to 900ml.
Embodiment two: the expression of erythropoietin
It is successive type cell reactor (the CELLIGEN PLUS of 5L that the cell jar adopts volume, NBS company makes), the PBS damping fluid (pH7.0) of adding 150 gram cellulose carrier sheets (Disc, LifeGen Co. produces), 3.5L, connect good pipeline, autoclaving is 1.5 hours under 121 ℃, 15 pounds.Treat to insert main frame after the cell jar is cooled to room temperature, connect four kinds of gases such as air, oxygen, carbonic acid gas and nitrogen, proofreaied and correct pH electrode and DO. electrode.Discharge the PBS damping fluid in the cell jar, adding 2500ml contains the DMEM substratum of 5% foetal calf serum, again 900ml cell inoculation liquid is slowly added in the cell jar, regulating revolution is 50rpm/ minute, feed four kinds of gases (oxygen, nitrogen, carbon dioxide gas and pressurized air), control DO.50%, pH7.0 makes cell attachment growth four hours.Improve revolution then by 80 rpm/ minutes, continued amplification cultivation ten days.Substratum is replaced with the synthetic medium of serum-free, and (every 10L contains CHO-S-SFM-II9L, gentamicin 500,000 units, Regular Insulin 1mM, Transferrins,iron complexes 20nM, glucose 25 grams, sodium bicarbonate 30.5 grams), cultural method with continuous perfusion substratum, use AFS software (design of NBS company is produced) control cell fermentation condition (37 ℃ of temperature, DO.40-80%, pH 6.5-7.5, substratum perfusion flow are 3L/ days), results liquid is in the storage down of 4-8 ℃ of low temperature.
Embodiment three: the purifying of hEPO
Get and obtain substratum 40L, use the 0.22um membrane filtration, what be splined on volume and be 2500ml uses 1.4MNaCl-40% Virahol-0.1M HAc 13000ml (pH 3.0) activation in advance, wash with the 10000ml tri-distilled water, use 20mM Tris (pH 7.0) 10000ml level pad equilibrated CM-Affi Blue Gel post (production of BioRad company) at last, last sample flow velocity is that the last sample of 30ml/min finishes, and uses level pad balance cylinder again, washes the foreign protein that can not adsorb off.The protein that adopts 0.2M NaCl-20mM Tris (pH 7.0) elutriant to carry out gradient elution absorption, elution speed 40ml/min.Collect elution peak 3000ml, protein content is 1mg/ml.With the protein solution of the collecting dialysis tubing of packing into,,, divide and change liquid four times by 15 times of volume calculation with 10mM Tris.HCl (pH 7.0) dialyzate dialyzed overnight.
With the protein soln of the desalination of dialysing 0.22um membrane filtration, being splined on volume is the Tris.HCl of 10mM in advance (pH 7.0) the 50000ml level pad equilibrated DEAE-Sepharose Fast Flow post (production of Parmacia company) of 2500ml, and last sample flow velocity is 4ml/min.Last sample finishes, and adopts the elutriant of 0.1M NaCl--Tris (pH 7.0) to carry out gradient elution, and elution flow rate is 40ml/min.Collect the 3rd elution peak 1800ml, protein content is 0.37mg/ml, makes the crude product that contains hEPO and prepare to be used for being further purified of RP-HPLC after sterile filtration.
Column packing is C4 (300A, 15um, Separation Group produce), column volume be RP-HPLC (Warters company produces, the 2000 types) chromatography column of 500ml with 10% acetonitrile solution (0.1% trifluoroacetic acid) balance, flow velocity is 60ml/min.Get sample on the 1800ml crude product, flow velocity is 15ml/min; Behind the end of the sample with 10% acetonitrile solution (containing 0.1% trifluoroacetic acid) balance C4 post.Acetonitrile solution with 10-70% carries out gradient elution again.Collect activated elution peak 330ml, protein content is 1.0mg/ml.
What gel-filtration was adopted is Sephades G-25 post (productions of Parmacia company), dress column volume 3000ml, and usefulness 20mM citrate buffer 6000ml balance is got sample on the sample behind the RP-HPLC purifying, and flow velocity is 1ml/min.Last sample finishes, and uses 20mM citrate buffer balance and wash-out again, collects elution peak 250ml, and protein content is 1.2mg/ml.The ratio that sampling is measured hEPO in the work in-process with microplate reader (Bio-Bad company produces, 3550 types) is lived, and measures protein concn with ultraviolet spectrophotometer (BECKMAN company produces, the DU-640 type); After quality inspection is qualified, add 0.5% human serum albumin and sterile filtration, make the hEPO finished product.Through the hEPO of this technological process of production purifying, it can reach 2 * 10 than work
5IU/mg.
Claims (2)
1. the method for an expressing human erythropoietin, comprise for the Chinese hamster ovary celI of the nucleotide sequence that contains the erythropoietin of encoding and cultivating, it is characterized in that, Chinese hamster ovary celI inoculation liquid amplification cultivation in the cell jar that will contain the nucleotide sequence of the erythropoietin of encoding earlier with the DMEM substratum that contains foetal calf serum, again substratum is replaced by the synthetic medium of serum-free, perfusion is cultivated continuously, contains Regular Insulin, Transferrins,iron complexes, sugar and sodium bicarbonate in the synthetic medium of described serum-free.
2. according to the process of claim 1 wherein that the synthetic medium of described serum-free is the CHO-S-SFM-II substratum, wherein contain Regular Insulin 1nM-10mM, Transferrins,iron complexes 0.1nM-100nM, glucose 1-10 grams per liter, sodium bicarbonate 2-4 grams per liter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB98100248XA CN1142281C (en) | 1998-01-19 | 1998-01-19 | Preparation of recombined erythropoietin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB98100248XA CN1142281C (en) | 1998-01-19 | 1998-01-19 | Preparation of recombined erythropoietin preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1190130A CN1190130A (en) | 1998-08-12 |
| CN1142281C true CN1142281C (en) | 2004-03-17 |
Family
ID=5215907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB98100248XA Expired - Fee Related CN1142281C (en) | 1998-01-19 | 1998-01-19 | Preparation of recombined erythropoietin preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1142281C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9905868A (en) * | 1998-11-06 | 2001-01-23 | Bio Sidus S A | Mass culture procedure for mammalian cells to obtain recombinant human erythropoietin and recombinant human erythropoietin obtained with such procedure |
| GB0711424D0 (en) * | 2007-06-13 | 2007-07-25 | Novozymes Delta Ltd | Recombinant transferrin mutants |
| DE102008054716A1 (en) * | 2008-12-16 | 2010-06-17 | Evonik Degussa Gmbh | In-process control in a process for the production of EPO |
-
1998
- 1998-01-19 CN CNB98100248XA patent/CN1142281C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1190130A (en) | 1998-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5214132A (en) | Polypeptide derivatives of human granulocyte colony stimulating factor | |
| US6027720A (en) | G-CSF conjugate | |
| US5714581A (en) | Polypeptide derivatives of human granulocyte colony stimulating factor | |
| CN117886923A (en) | Recombinant humanized collagen and encoding gene and application thereof | |
| RU2054044C1 (en) | Method of preparing human recombinant gamma-interferon without n-terminal methionine | |
| JPH06113879A (en) | Human viii factor and preparation of analog of human viii factor | |
| CN1142281C (en) | Preparation of recombined erythropoietin preparation | |
| CN1036934C (en) | Preparation method of isohirudin with improved stability | |
| RU2215748C2 (en) | Method for preparing recombinant human erythropoietin and prepared erythropoietin, pharmaceutical composition | |
| JP3805378B2 (en) | Method for producing rDSPAα1 | |
| CN1137897C (en) | Process for preparing recombined human thrombopoietin preparation | |
| CN108484749B (en) | Recombinant soluble human bone-targeted interferon gamma-1 b and preparation method thereof | |
| JP3200850B2 (en) | Purification method of human BCDF | |
| CN107435045B (en) | A kind of nucleotide sequence and solution expression with high efficiency method of optimum combination Human Inter Leukin-2 | |
| CN1058992C (en) | Recombinative human thrombocytopoietic factor and production thereof | |
| RU2201962C2 (en) | Method of preparing human recombinant granulocytic colony-stimulating factor | |
| CN1259336C (en) | A kind of purification method of compound interferon | |
| CN1061992C (en) | Colony stimulating factor for recombination of human granulocytes and medicinal composition thereof | |
| CN112209999B (en) | Method for quickly separating pigment in recombinant epidermal growth factor fermentation liquor | |
| JPH06256399A (en) | Purification of human interleukin 11 | |
| CN1051092C (en) | Process for preparing recombinated interleukin-2 | |
| CN102094034A (en) | Process for purifying recombinant human Fc fusion pegylated interferon | |
| US5641868A (en) | Interlekin-6 compositions, and a production process thereof | |
| CN1368507A (en) | Process for purifying stem cell factor | |
| RU2487885C2 (en) | Method for large-scale production, separation and purification of recombinant human granulocyte colony-stimulating factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |